Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rechARge: Phase 3 study of BMS-986365 versus investigator's choice therapy in metastatic castration-resistant prostate cancer
CTR20252534Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Sep 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BMS-986365 in prostate cancer (PCa), sponsored by Celgene Corporation. Started Sep 2025; status: terminated.
02
Drugs
BMS-986365
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20252534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252534.